MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    The impact of multimodal forms of art therapy on treatment outcomes and quality of life in Parkinson’s disease

    L. čondić Jurjević, S. Telarović (Sisak, Croatia)

    Objective: Assessing the impact of art therapy on treatment outcomes and quality of life in Parkinson's disease (PD). Background: In addition to medical treatment, art…
  • 2024 International Congress

    Comparative-effectiveness of Foscarbidopa/foslevodopa (LDp/CDp) versus Oral Therapies in Advanced Parkinson’s Disease: A Propensity Matched Study

    D. Standaert, A. Fasano, F. Ory-Magne, D. Kern, O. de Fabregues, T. Oeda, D. Safarpour, Z. Baldwin, C. Yan, S. Wang, K. Onuk, P. Kukreja, L. Bergmann, V. Fung (Birmingham, USA)

    Objective: To assess long-term effectiveness outcomes in people with advanced Parkinson’s Disease (aPD) on LDp/CDp versus those on oral PD therapies (standard of care, SoC).…
  • 2024 International Congress

    An observational study of the efficacy, safety, and discontinuation rate of foslevodopa/foscarbidopa in 22 patients with advanced Parkinson’s disease

    D. Kamiyama, N. Nishikawa, C. Abe, H. Iwaki, G. Oyama, T. Hatano, N. Hattori (Bunkyo, Japan)

    Objective: The aim of this observational study for PD patients treated with foslevodopa/foscarbidopa(LDP/CDP) is to evaluate clinical characteristics, therapeutic efficacy and safety, and to determine…
  • 2024 International Congress

    Bidirectional interplay between DBS and cognition in Parkinson’s disease: a systematic review

    V. Sisodia, A. Malekzadeh, E. Verwijk, P. Schuurman, R. de Bie, B. Swinnen (Amsterdam, Netherlands)

    Objective: To evaluate the evidence regarding (1) deep brain stimulation (DBS) effectiveness in case of postoperative cognitive deterioration, (2) the impact of preoperative cognition on…
  • 2024 International Congress

    Baseline Variables Associated with Apomorphine Sublingual Film Retention

    J. Kassubek, J. Schwarz, L. López Manzanares, M. Fonseca, C. Denecke Muhr (Ulm, Germany)

    Objective: The aim of this analysis was to identify the baseline variables that differ between patients who completed Study CTH-301 and those who discontinued during…
  • 2024 International Congress

    Aerobic Exercise in Non-Exercisers with Advanced Parkinson’s Disease (PD) and Deep Brain Stimulation (DBS): A Pilot Study

    S. Aslam, M. Olson, S. Felson, F. Ponce, H. Shill (Aurora, USA)

    Objective: To assess the feasibility of an aerobic exercise regimen in those with advanced PD and DBS. Background: Aerobic exercise is known to have beneficial…
  • 2024 International Congress

    If Oral Levodopa is not Possible, Keep Calm and Breathe Deeply

    D. García-Meléndez, E. Gisbert Tijeras, B. Carmona Moreno, E. Botia Paniagua (Alcázar San Juan, Spain)

    Objective: Include inhaled levodopa as a therapeutic option in those patients who, due to post-surgical problems, cannot use oral treatments. Background: The development of motor…
  • 2024 International Congress

    Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain

    D. Saturnino Guarino, G. Tian, K. Ho Young, H. Cj, V. Lee, K. Luk, R. Mach (Philadelphia, USA)

    Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…
  • 2024 International Congress

    Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations

    R. Pahwa, T. van Laar, K. Dashtipour, G. Ceresoli-Borroni (Kansas City, USA)

    Objective: Review available efficacy data from Phase 3 studies assessing continuous subcutaneous apomorphine infusion (CSAI) for patients with PD experiencing motor fluctuations. Background: Despite decades…
  • 2024 International Congress

    Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up

    R. Hauser, V. Fung, T. Kimber, K. Klos, M. Facheris, A. Jeong, J. Jia, A. Spiegel, M. Soileau (Tampa, USA)

    Objective: Evaluate long-term safety and efficacy of foslevodopa/foscarbidopa (LDp/CDp) among people with advanced Parkinson’s disease (aPD). Background: As aPD progresses, erratic gastric emptying and pulsatile…
  • « Previous Page
  • 1
  • …
  • 412
  • 413
  • 414
  • 415
  • 416
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley